Wednesday, March 22, 2023
Home Biotech News Stem Cells

Stem Cells

    Latest
    Biotech Stock Review

    Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.

    2021 Watch List Editor / Curator -
    Added to Watch List November 2019 @$0.55. Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021...

    The FDA Cracks Down On Stem Cell Therapy.

    Stem Cells Editor / Curator -
    Due to a somewhat unexpected crackdown on stem cell treatment centers a couple of weeks ago - we have decided to hold...
    Issam Radd

    Citius (CTXR): Halt For Superiority On The Horizon? (SeekingAlpha).

    2021 Watch List Editor / Curator -
    Jun. 15, 2021 10:41 AM ET Citius Pharmaceuticals, Inc. (CTXR) Summary
    Biotech Stock Review. Citius, CTXR

    More Great News From Citius Pharma (CTXR).

    Incubator Editor / Curator -
    UPDATED CHART 6-15-21 Mino-Lok® Phase III, FDA NewsRussell 2000 Index NewsTechnical Breakout News
    Internet Stock Review

    Stocks On The Move!

    Stem Cells Editor / Curator -
    Citius (CTXR) up 19%, Draganfly (DFLYF) up 31%, urban-gro (UGRO) up 37%, Provention (PVRB) flip-flopping, Hapbee Technologies (HAPBF) up 26% and the...
    Dalarada, Internet Stock Review

    Discontinuing Coverage on Dalrada (DFCO).

    Stem Cells Editor / Curator -
    We Are Temporarily Discontinuing Coverage on Dalrada Financial. Great little company and we're up 400%. But with the market...

    Citius Pharma (CTXR) Updates Shareholders.

    CoronaVirus Editor / Curator -
    Citius Update Stem Cell Study Citius Pharmaceuticals, Inc announced that it will present a poster at the International Society...
    Stem Cell Stock Review

    Old News, But Wow: Starr Foundation Reaffirms Support for Stem Cell Research with $50...

    Stem Cells Editor / Curator -
    Someone is a Big Believer and Cutting Equally Big Checks! NEW YORK (April 4, 2019) — The Starr...

    Stem Cell Play Organicell (BPSR) Screams Higher.

    Stem Cells Editor / Curator -
    Stock Levitates After Series of Positive Press Releases on Zofrin. Added to the Watch List in April a...
    Citius, Leonard Mazur

    Interview: Citius Pharma (CTXR) $1.74, Chairman Leonard Mazur.

    Stem Cells Editor / Curator -
    https://youtu.be/vMIy8xWLOKI?t=3699 Starts at 1 Hour Mark. INSIDER HOLDINGS
    123Page 1 of 3

    Latest article

    IA Initiates Analyst Coverage of Principal Solar (Press Release).

    Alternative Energy Editor / Curator -
    Principal Solar, Inc.Mon, March 20, 2023 at 7:30 AM EDT Institutional Analyst, Inc....

    Selling ARK (ARKK) & Buying AXS Short Innovation (SARK) ETF.

    All News Editor / Curator -
    Going Short the Market. No Long Dissertation, No Rush. Market Risk Has Appeared, With Minimal Upside, So Time To Act.

    We’re Bearish, but we’re up 257% in Provention Bio (PRVB) Today.

    2022 Watch List Editor / Curator -
    And up 416%, from Adding it to 2022 Watch List! Great way to wake up after a night of...
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: roland@institutionalanalyst.com
    © Managed by Revelers.IO Media Group Inc.